recognized.
Significant male infertility is mainly associated with XXY males (see Chapter 12), autosomal translocations, Kallman syndrome, Y‐microdeletions, autosomal inversions, CBAVD, mixed gonadal dysgenesis, and X‐linked and autosomal gene mutations.504 We reported a 28‐year‐old with azoospermia and bilateral congenital cataracts associated with a contiguous deletion including the Nance–Horan gene at Xp23.13 and implicating the SCML1 gene.505 The global prevalence of Yq microdeletions approximates 7.5 percent in infertile males.506 Genes including DAZ (“deleted in azoospermia”), YRRM (Y chromosome RNA recognition motif),507, 508 and others may be deleted singly or together in the region of Yq11.23.509 Couples must be informed that male offspring of men with these interstitial deletions in the Y chromosome will have the same structural chromosome defect. The female partner of the male undergoing intracytoplasmic sperm injection (ICSI) needs explanations about procedures and medications for her that are not risk free. Patients should realize that ICSI followed by IVF is likely to achieve pregnancy rates between 20 and 24 percent,510 a success rate not very different from the approximately 30 percent rate in a single cycle after natural intercourse at the time of ovulation.510 Pregnancy follow‐up data from cases culled from 35 different programs reported in a European survey511 and a major American study of 578 newborns showed no increased occurrence of congenital malformations.214 However, a statistically significant increase in sex chromosome defects has been observed.512 Prenatal diagnosis is recommended in all pregnancies following ICSI.
Even “balanced” reciprocal translocations in males may be associated with the arrest of spermatogenesis and resultant azoospermia.513 In one series of 150 infertile men with oligospermia or azoospermia, an abnormal karyotype was found in 10.6 percent (16/180), 5.3 percent (8/150) had an AZF‐c deletion, and 9.3 percent (14/150) had at least a single CF gene mutation.514 This study revealed a genetic abnormality in 36/150 (24 percent) of men with oligospermia or azoospermia. A Turkish study of 1,696 males with primary infertility showed 8.4 percent with a chromosomal abnormality and 2.7 percent with a Y‐chromosome microdeletion.515
Rarer disorders may need to be considered in the quest to determine the cause of infertility including, for example, the blepharophimosis, ptosis, epicanthus inversus syndrome, which may respond to treatment.516
In a study of 75,784 women to determine all‐cause and cause‐specific mortality, those with infertility had a 10 percent increased risk of death from any cause.517 Death from breast cancer was more than doubled. In a major prospective Danish study, 3,356 women who had children born after frozen embryo transfer were compared with 910,291 fertile women. The incidence rate of childhood cancer was 17.5 per 100,000 for children born to fertile women, and 44.4 per 100,000 in children born after the use of frozen embryos.518 The statistically significant increased risk was primarily leukemia and sympathetic nervous system tumors. The cause(s) remain unknown. A US study did not find a significant association, but had a shorter follow‐up period (<5 years), follow‐up loss, and incomplete maternal data.519 In a retrospective study using insurance data, the records of 19,658 infertile women and 525,695 fertile women were examined to determine severe maternal morbidity.520 The overall incidence of severe maternal morbidity among women receiving fertility treatment was 7.0 percent compared with 4.3 percent in fertile women.
Parental carrier of a genetic disorder
Prospective healthy parents are mostly unaware of their carrier status for a chromosomal or single‐gene disorder, unless their medical or reproductive history has otherwise been informative. Studies to determine prenatal carrier status for a chromosomal disorder are recommended following a history of recurrent miscarriage, previous stillbirth, previous child with intellectual disability, or congenital abnormality, infertility, oligospermia, azoospermia, or a family history that is concerning for any of these outcomes. Chromosome analysis will mostly suffice in determining translocations, inversions, and somatic mosaicism. Chromosomal microarrays (see Chapter 13) for both parents are appropriate if no diagnosis was made for previous affected progeny, but will miss balanced translocations.
The first preconception visit is the time to establish the carrier status of a couple for either a chromosomal or monogenic disorder.521 Among the many items to be considered during the preconception visit are the potential physical features indicative of sex‐linked disorders that may manifest in female carriers (see discussion later). With or without a family history of the disorder in question, referral to a clinical geneticist would be appropriate for final evaluation of possible implications. Failure to recognize obvious features in a manifesting female may well result in a missed opportunity for prenatal genetic studies and an outcome characterized by a seriously affected male (or occasionally female) offspring. Recognition of the carrier status for Duchenne muscular dystrophy (DMD) of a prospective mother at the first preconception visit should immediately include consideration of her own future health. Some two‐thirds of mothers are carriers of a DMD gene mutation. As X‐linked carriers they may manifest symptoms and signs of this disorder, including muscle weakness, prominent but weak calf muscles, abnormal gait, fatigue, exercise intolerance, and, of greatest importance, heart involvement.522 Up to 16.7 percent of DMD carriers develop dilated cardiomyopathy, with carriers of Becker muscular dystrophy (BMD) having up to a 13.3 percent risk.523 The cardiomyopathy may also manifest with conduction defects and arrhythmias.522, 524–527 While most carriers become symptomatic around puberty,528 the risks and severity increase with age. Unfortunately, physicians are often unaware of the risks DMD carriers face,529 despite having elevated levels of creatine phosphokinase.530 In a study of 77 DMD and BMD carriers with a molecular confirmed diagnosis, 49 percent had myocardial fibrosis detected by cardiac MRI.531 Irreversible heart failure maybe the final complication for which cardiac transplantation has been done.532
A report on 355 fragile X carrier women noted that >30 percent complained of anxiety, depression, and headaches.533 Between 20 and 30 percent of carriers experience irregular or absent menses due to primary ovarian insufficiency.534 This latter recognition during routine obstetric care often serves as an alert to check fragile X syndrome carrier status. We have also seen instances where recognition of carrier status has led to reversal of a putative diagnosis of parkinsonism or early dementia, instead of an actual diagnosis of the fragile X tremor ataxia syndrome manifesting in a grandfather over 60 years of age (see Chapter 16).
Carrier status for women with a family history of hemophilia A or B cannot be excluded by a normal activated partial thromboplastin time or normal factor VIII or factor IX levels.535 A definitive molecular diagnosis combined with linkage analysis where necessary is needed, especially if prenatal or preimplantation diagnosis is sought. Determination of a pathogenic variant in the structurally complex factor VIII gene enables confirmation of carrier status.536, 537 Prenatal diagnosis requests for hemophilia A are uncommon, but have been provided.538–540 Preimplantation genetic testing (see Chapter 2) for hemophilia has also been accomplished.541 Noninvasive prenatal diagnosis of hemophilia A and B in hemophilia carriers using maternal plasma and factor VIII and factor IX sequence variants has been demonstrated542 (see Chapter 8).
We all carry a host of deleterious recessive genes (∼100–300)543 and technical advances have enabled routine simultaneous testing of hundreds of autosomal recessive and X‐linked disorders which affect about 1 in 300 pregnancies.544 Not well understood by patients is the fact
